Cargando…

Immunotherapy in Gastrointestinal Cancers

Gastrointestinal cancers represent a major public health problem worldwide. Immunotherapeutic strategies are currently under investigation in this setting and preliminary results of ongoing trials adopting checkpoint inhibitors are striking. Indeed, although a poor immunogenicity for GI has been rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Procaccio, Letizia, Schirripa, Marta, Fassan, Matteo, Vecchione, Loredana, Bergamo, Francesca, Prete, Alessandra Anna, Intini, Rossana, Manai, Chiara, Dadduzio, Vincenzo, Boscolo, Alice, Zagonel, Vittorina, Lonardi, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512095/ https://www.ncbi.nlm.nih.gov/pubmed/28758114 http://dx.doi.org/10.1155/2017/4346576

Ejemplares similares

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
por: Prete, Alessandra Anna, et al.
Publicado: (2022)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Microsatellite Instable Colorectal Adenocarcinoma Diagnostics: The Advent of Liquid Biopsy Approaches
por: Ceccon, Carlotta, et al.
Publicado: (2022)

A Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
por: Procaccio, Letizia, et al.
Publicado: (2021)

Simultaneous care in oncology: Assessment of benefit in relation to symptoms, sex, and age in 753 patients
por: Galiano, Antonella, et al.
Publicado: (2022)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy
por: Brunello, Antonella, et al.
Publicado: (2022)

Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair–deficient metastatic colorectal cancer: Immunological and molecular profiling
por: Bergamo, Francesca, et al.
Publicado: (2022)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

Bone metastases from neuroendocrine tumors: clinical and biological considerations
por: Scopel, Matteo, et al.
Publicado: (2022)

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
por: Pellino, Antonio, et al.
Publicado: (2019)

Immune senescence and immune activation in elderly colorectal cancer patients
por: Giunco, Silvia, et al.
Publicado: (2019)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

Antigen rapid diagnostic test monitoring for SARS‐CoV‐2 in asymptomatic and fully vaccinated cancer patients: Is it cost‐effective?
por: Caccese, Mario, et al.
Publicado: (2022)

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
por: Lonardi, Sara, et al.
Publicado: (2021)

Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
por: Bergamo, Francesca, et al.
Publicado: (2014)

Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
por: Pellino, Antonio, et al.
Publicado: (2021)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
por: Cremolini, Chiara, et al.
Publicado: (2017)

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter
por: Businello, Gianluca, et al.
Publicado: (2022)

Safety of COVID-19 Vaccine in Patients with Cancer in a High-Volume Comprehensive Cancer Center
por: Brunello, Antonella, et al.
Publicado: (2022)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases
por: Loupakis, Fotios, et al.
Publicado: (2021)

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2020)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
por: Angerilli, Valentina, et al.
Publicado: (2021)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Claudin-18 expression in small bowel adenocarcinoma: a clinico-pathologic study
por: Arpa, Giovanni, et al.
Publicado: (2022)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Mesenchymal tumours of the gastrointestinal tract
por: Sbaraglia, Marta, et al.
Publicado: (2021)

Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
por: Gallois, Claire, et al.
Publicado: (2023)

Intratumor morphologic and transcriptomic heterogeneity in (V600E)BRAF-mutated metastatic colorectal adenocarcinomas
por: Angerilli, V., et al.
Publicado: (2021)

Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
por: Vicentini, Caterina, et al.
Publicado: (2014)

Renal cell carcinoma: the population, real world, and cost-of-illness
por: Buja, Alessandra, et al.
Publicado: (2022)

Patient Reported Outcomes, Paternity, Relationship, and Fertility in Testicular Cancer Survivors: Results from a Prospective Observational Single Institution Trial
por: Bimbatti, Davide, et al.
Publicado: (2022)

Prognostic Stratification of Metastatic Prostate Cancer Patients Treated With Abiraterone and Enzalutamide Through an Integrated Analysis of Circulating Free microRNAs and Clinical Parameters
por: Sharova, Evgeniya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1p5e177l34otejq5tha1lgmnmj